TNF Inhibitor denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies TNF Inhibitors as "Not FDA-Approved"

This type of denial typically arises in one of two scenarios: (1) the TNF inhibitor is being used for an indication not listed in its FDA-approved labeling (an "off-label" use), or (2) there is a documentation gap — the submitted records did not clearly link the prescription to an approved indication, so the reviewer defaulted to a "not FDA-approved" denial. Understanding which scenario applies is the critical first step before appealing.

## Why This Denial Is Appealable

If the use is on-label: The denial may rest on a documentation error. Correcting the record — with a clear prescriber letter tying the drug to its approved indication — can resolve this quickly through internal appeal.

If the use is genuinely off-label: Off-label use is not automatically excluded. Many plans cover off-label use that is supported by recognized medical compendia (such as DrugDex or the NCCN Drugs and Biologics Compendium) or by peer-reviewed evidence. Under ACA §2719 and ERISA §503, you have full internal-appeal and external-review rights, and an IRO must evaluate the clinical evidence independently.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice; include all clinical documentation and the prescriber's rationale.
• External review: Available after exhausting internal appeal; independent reviewers are required to apply recognized clinical standards, not solely the insurer's formulary policy.
• Expedited option: Request if the standard timeline would seriously jeopardize your health.

## Documentation to Gather

1. Indication clarity — a prescriber letter explicitly naming the diagnosis, the ICD-10 code, and tying the TNF inhibitor to either its FDA-approved labeling or a recognized compendia/guideline-supported off-label use. 2. FDA label reference — a copy of (or citation to) the current FDA-approved prescribing information confirming the labeled indication, obtained from DailyMed or the manufacturer. 3. Compendia or guideline support (if off-label) — identification of the specific compendium entry or specialty organization guideline (e.g., ACR, ACG, AAD) endorsing this use. 4. Clinical necessity — chart documentation establishing diagnosis, disease severity, and prior treatment history supporting the prescribing decision. 5. Peer-reviewed literature (if off-label and compendia coverage is absent) — the prescriber's summary of the clinical evidence base.

## Criteria-Mapping Structure

Map each of UHC's coverage-determination criteria against the available evidence:

| Denial Basis | Rebuttal Evidence | |---|---| | Not in FDA labeling | FDA label confirms indication, OR compendia entry supports off-label use | | No recognized guideline support | Specialty guideline organization citation from prescriber letter | | Documentation gap | Amended prescriber letter with explicit indication–drug linkage |

Always start by downloading the current FDA-approved prescribing information from DailyMed and confirming UHC's current coverage policy for this indication before drafting your appeal.